Individualization of lymph node dissection in RET (Rearranged during Transfection) carriers at risk for medullary thyroid cancer: Value of pretherapeutic calcitonin levels

Annals of Surgery

Volumn 250, Issue 2, 2009, Pages 305-310

  MacHens, Andreas ^a   Lorenz, Kerstin ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; GENOMIC DNA; PROTEIN RET; RET PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CELL HYPERPLASIA; CERVICAL LYMPH NODE; CHILD; CODON; FEMALE; GENETIC RISK; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REOPERATION; SCHOOL CHILD; THYROID GLAND; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; AGE; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GENETICS; LYMPHADENECTOMY; MEDULLARY CARCINOMA; MUTATION; PATHOLOGY; PREDICTION AND FORECASTING; THYROID TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; CALCITONIN; CARCINOMA, MEDULLARY; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; FEMALE; HETEROZYGOTE; HUMANS; LYMPH NODE EXCISION; MALE; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 68949131275     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181ae333f     Document Type: Article

References (35)

1. Lips CJ, Landsvater RM, Höppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331:828-835.
2. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220:237-250. (Pubitemid 24313219)
3. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience: World J Surg. 1998;22:744-751.
4. Donis-Keller H, Dou S, Chi D, et al. Mutations of the RET protooncogene are associated with MEN2A and FMTC. Hum Mol Genet. 1993;2:851-856.
5. Mulligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363: 458-460.
6. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlation in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab. 2001;86:1104-1109.
7. Niccoli-Sire P, Murat A, Rohmer V, et al. Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship on a large series of patients. J Clin Endocrinol Metab. 2001;86:3746-3753.
8. Brandi ML, Gagel RF, Angeli A, et al. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86: 5658-5671.
9. Machens A, Niccoli-Sire-P, Högel J, et al; European Multiple Endocrine Neoplasia (EUROMEN) Study Group: early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349:1517-1725.
10. Machens A, Holzhausen HJ, Thanh PN, et al. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery. 2003;134:425-431.
11. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007;31:957-968.
12. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105-1113.
13. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245:604-610.
14. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029-2034.
15. Ukkat J, Lorenz K, Hinze R, et al. Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers. World J Surg. 2001;25:713-717.
16. Machens A, Hauptmann S, Dralle H. Referral bias in thyroid cancer: direction and magnitude. Eur J Surg Oncol. 2008;34:556-562.
17. Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg. 2008;95:586-591.
18. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J. 1995;310:170.
19. Simon S, Pavel M, Hensen J, et al. Multiple endocrine neoplasia 2A syndrome: surgical management. J Pediatr Surg. 2002;37:897-900.
20. Igaz P, Patocs A, Rácz K, et al. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET protooncogene. J Clin Endocrinol Metab. 2002;87:2994.
21. Machens A, Schneyer U, Holzhausen HJ, et al. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. Surgery. 2004;136:1083-1087.
22. Farahati J, Reiners C, Demidchik EP. Is the UICC/AJCC classification of primary tumor in childhood thyroid carcinoma valid? J Nucl Med. 1999;40: 2125.
23. Hennekins CH, Buring JE, Mayrent SL. Epidemiology in Medicine. Boston/ Toronto: Little, Brown and Company; 1987.
24. Leboulleux S, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer. 2002;94:44-50.
25. Gill JR, Reyes-Múgica M, Iyengar S, et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr. 1996;129:459-464.
26. Decker RA, Peacock ML. Update on the profile of multiple endocrine neoplasia type 2a RET mutations: practical issues and implications for genetic testing. Cancer. 1997;80:557-568.
27. Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery. 2000;128:1052-1057; discussion 1057-1058.
28. Tamanaha R, Camacho CP, Ikejiri ES, et al. Y791F RET mutation and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of phenotype-modifying effect of germline variants. Clin Endocrinol. 2007;67: 805-808.
29. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg. 2004;28:1312-1316.
30. Fugazzola L, Cerutti N, Mannavola D, et al. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin Endocrinol. 2002;56:53-63.
31. Oriola J, Páramo C, Halperin I, et al. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma. Am J Med Genet. 1998;78:271-273.
32. Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol. 2008;69:81-87.
33. Machens A, Gimm O, Ukkat J, et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer. 2000;88:1909-1915.
34. Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001;130:1044-1049.
35. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070-2075.